AAA
LXEO icon

Affinity Asset Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Affinity Asset Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Buy
5,807,611
+757,400
+15% +$4.1M 1.22% 24
2026
Q1 		$29M Buy
5,050,211
+1,850,211
+58% +$13.1M 1.5% 20
2025
Q4 		$31.8M Sell
3,200,000
-670,527
-17% -$6.12M 1.81% 18
2025
Q3 		$25.7M Buy
3,870,527
+281,172
+8% +$1.36M 2.24% 16
2025
Q2 		$14.4M Buy
3,589,355
+2,108,474
+142% +$6.93M 1.97% 13
2025
Q1 		$5.14M Buy
+1,480,881
New +$6.56M 0.49% 41

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Affinity Asset Advisors's LXEO Position: Q2 2026 in Review

Affinity Asset Advisors increased its Lexeo Therapeutics (LXEO) stake by 15% in Q2 2026, buying an estimated $4.1M and bringing the position to 5,807,611 shares worth $27M. The position accounts for 1.22% of the portfolio, ranked #24.

Affinity Asset Advisors first reported a position in LXEO in Q1 2025 and has held it in 6 quarters since. The position peaked at $31.8M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Affinity Asset Advisors held 5,807,611 shares of Lexeo Therapeutics worth $27M as of Q2 2026.
  • Affinity Asset Advisors bought 757,400 Lexeo Therapeutics shares in Q2 2026, an estimated $4.1M.
  • Lexeo Therapeutics made up 1.22% of Affinity Asset Advisors's portfolio in Q2 2026, its #24 holding.
  • Affinity Asset Advisors first reported a position in Lexeo Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Affinity Asset Advisors's Lexeo Therapeutics position peaked at $31.8M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.